NEW YORK (GenomeWeb News) – Asterand said today that it has extended its drug-discovery and development collaboration with Bristol-Myers Squibb for up to three years.
Under the agreement, BMS will continue to have access to Asterand's PhaseZERO drug-discovery services and XpressBANK human tissue and clinical sample bank for early drug-target validation and compound optimization.
BMS may also use Asterand's ProCURE custom clinical sample collection service, Asterand said.
BMS originally inked a research collaboration with Asterand predecessor Pharmagene in 2001, and the companies have renewed the agreement several times. Pharmagene became a part of Asterand in 2006 through a reverse merger.
Asterand is based in Royston, UK, and Detroit, Michigan, and supplies human tissue and tissue-based services for drug discovery and development.